A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
- Sponsor
- Genentech, Inc.
- Study ID
- NCT00337883
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Erlotinib HCl (OSI-774) — DRUG
Study Details
This is a Phase II, open-label, multicenter trial of single-agent treatment with Tarceva in patients with histologically confirmed GBM in first relapse. This study seeks to estimate the objective response rate and will investigate whether response rate is related to EGFR amplification status.
Key Dates
- First listed
- Jun 20, 2006
- Start date
- Jul 31, 2003
- Status verified
- Feb 2014
- Completion
- Oct 31, 2005
Study Design
- Enrollment
- 110 participants
- Primary purpose
- TREATMENT
Related Studies
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York
- Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed GlioblastomaPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)PHASE2 · Recruiting · Patrick Wen, MD · Birmingham, Alabama
- Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBMPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York